PE20221907A1 - Preparacion de un compuesto que inhibe mcl-1 mediante metilacion en presencia de agua - Google Patents
Preparacion de un compuesto que inhibe mcl-1 mediante metilacion en presencia de aguaInfo
- Publication number
- PE20221907A1 PE20221907A1 PE2022002152A PE2022002152A PE20221907A1 PE 20221907 A1 PE20221907 A1 PE 20221907A1 PE 2022002152 A PE2022002152 A PE 2022002152A PE 2022002152 A PE2022002152 A PE 2022002152A PE 20221907 A1 PE20221907 A1 PE 20221907A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- water
- period
- methylation
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Refiere a un proceso mejorado para sintetizar un compuesto (A), una sal o solvato de este, el cual comprende: (a) mezclar una base que comprende hexametildisilaziduro de potasio ("KHMDS") con una solucion que comprende el compuesto B o una sal o solvato de este, un disolvente de tipo eter que comprende tetrahidrofurano ("THF"), un disolvente apolar y agua en una relacion molar de 0.1:1 a 3:1 con dicho compuesto, en un periodo de 5 segundos, y agitar en un periodo de 1 segundo a 20 minutos; y (b) mezclar la mezcla del paso (a) y MeX en un periodo de 5 segundos y agitar por aproximadamente 1-20 minutos para formar una mezcla que comprende el compuesto A. Asimismo, se menciona la produccion de un hidrato cristalino del compuesto (A) en presencia de acido acetico, etanol y agua para su uso en una formulacion farmaceutica junto a un excipiente farmaceuticamente aceptable.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002629P | 2020-03-31 | 2020-03-31 | |
| US202063070630P | 2020-08-26 | 2020-08-26 | |
| US202063084367P | 2020-09-28 | 2020-09-28 | |
| PCT/US2021/024779 WO2021202452A1 (en) | 2020-03-31 | 2021-03-30 | Preparation of mcl-1 inhibiting compound by methylation in the presence of water |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221907A1 true PE20221907A1 (es) | 2022-12-23 |
Family
ID=75581687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002152A PE20221907A1 (es) | 2020-03-31 | 2021-03-30 | Preparacion de un compuesto que inhibe mcl-1 mediante metilacion en presencia de agua |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230117777A1 (es) |
| EP (1) | EP4126883A1 (es) |
| JP (2) | JP2021161114A (es) |
| KR (1) | KR20220161368A (es) |
| CN (1) | CN115397828A (es) |
| AU (2) | AU2021246447B2 (es) |
| BR (1) | BR112022019761A2 (es) |
| CA (1) | CA3175912A1 (es) |
| CL (1) | CL2022002665A1 (es) |
| CO (1) | CO2022013968A2 (es) |
| CR (1) | CR20220490A (es) |
| IL (1) | IL296447A (es) |
| MX (1) | MX2022012240A (es) |
| PE (1) | PE20221907A1 (es) |
| TW (1) | TW202140479A (es) |
| UY (1) | UY39153A (es) |
| WO (1) | WO2021202452A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3099152C (en) | 2018-05-14 | 2023-10-24 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| KR20220105661A (ko) | 2019-11-26 | 2022-07-27 | 길리애드 사이언시즈, 인코포레이티드 | Mcl1 억제제를 제조하기 위한 방법 및 중간체 |
| WO2023150249A1 (en) * | 2022-02-04 | 2023-08-10 | Amgen Inc. | Crystalline forms of an mcl-1 inhibitor |
| WO2023150250A1 (en) * | 2022-02-04 | 2023-08-10 | Amgen Inc. | Crystalline salt and solvate forms of murizatoclax (amg 397) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6453507B2 (ja) * | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
-
2021
- 2021-03-23 JP JP2021048172A patent/JP2021161114A/ja active Pending
- 2021-03-30 CA CA3175912A patent/CA3175912A1/en active Pending
- 2021-03-30 IL IL296447A patent/IL296447A/en unknown
- 2021-03-30 CN CN202180025437.9A patent/CN115397828A/zh active Pending
- 2021-03-30 JP JP2022558429A patent/JP2023519680A/ja active Pending
- 2021-03-30 MX MX2022012240A patent/MX2022012240A/es unknown
- 2021-03-30 EP EP21720126.8A patent/EP4126883A1/en active Pending
- 2021-03-30 PE PE2022002152A patent/PE20221907A1/es unknown
- 2021-03-30 KR KR1020227036661A patent/KR20220161368A/ko unknown
- 2021-03-30 WO PCT/US2021/024779 patent/WO2021202452A1/en active Application Filing
- 2021-03-30 AU AU2021246447A patent/AU2021246447B2/en active Active
- 2021-03-30 CR CR20220490A patent/CR20220490A/es unknown
- 2021-03-30 US US17/910,042 patent/US20230117777A1/en active Pending
- 2021-03-30 BR BR112022019761A patent/BR112022019761A2/pt unknown
- 2021-03-31 TW TW110111735A patent/TW202140479A/zh unknown
- 2021-04-05 UY UY0001039153A patent/UY39153A/es unknown
-
2022
- 2022-09-29 CO CONC2022/0013968A patent/CO2022013968A2/es unknown
- 2022-09-29 CL CL2022002665A patent/CL2022002665A1/es unknown
-
2024
- 2024-02-05 AU AU2024200688A patent/AU2024200688A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220490A (es) | 2022-11-10 |
| BR112022019761A2 (pt) | 2022-11-16 |
| MX2022012240A (es) | 2022-10-27 |
| CO2022013968A2 (es) | 2022-10-31 |
| IL296447A (en) | 2022-11-01 |
| UY39153A (es) | 2021-10-29 |
| JP2021161114A (ja) | 2021-10-11 |
| CN115397828A (zh) | 2022-11-25 |
| JP2023519680A (ja) | 2023-05-12 |
| CA3175912A1 (en) | 2021-10-07 |
| TW202140479A (zh) | 2021-11-01 |
| US20230117777A1 (en) | 2023-04-20 |
| CL2022002665A1 (es) | 2023-06-09 |
| WO2021202452A1 (en) | 2021-10-07 |
| AU2021246447A1 (en) | 2022-10-13 |
| AU2021246447B2 (en) | 2023-11-16 |
| EP4126883A1 (en) | 2023-02-08 |
| KR20220161368A (ko) | 2022-12-06 |
| AU2024200688A1 (en) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221907A1 (es) | Preparacion de un compuesto que inhibe mcl-1 mediante metilacion en presencia de agua | |
| US11464790B2 (en) | Triterpenoids with HIV maturation inhibitory activity | |
| AU2005253732C1 (en) | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel | |
| PT1526839E (pt) | Formas farmacêuticas orais de fármacos líquidos com biodisponibilidade melhorada | |
| PE20040418A1 (es) | Nuevas formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion | |
| JP6131063B2 (ja) | 液体急結剤、それを用いたセメント組成物および吹付け工法 | |
| WO2009022899A1 (es) | Gel conteniendo pirfenidona | |
| ES2246878T3 (es) | Esteres nitricos amorfos y sus composiciones farmaceuticas. | |
| BR112016004990A2 (pt) | Composição para aplicaçãoo em uma mucosa compreendendo um éter de celulose | |
| BRPI0614197A2 (pt) | composiÇço, formas de administraÇço, processo para a preparaÇço da composiÇço, ingredientes ativos indometacina e acemetacina, e, uso da composiÇço | |
| ES2588770T3 (es) | Derivados de benzoquinona para el tratamiento de enfermedades oculares mitocondriales | |
| BR0206730A (pt) | Processo para preparar uma composição de valproato de sódio não-higroscópica, composição farmacêutica não-higroscópia e seu uso | |
| JP6450356B2 (ja) | 液状医薬製剤 | |
| JP2007099763A (ja) | ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法 | |
| WO2016077561A1 (en) | Oxolupene derivatives | |
| DE60222591T2 (de) | Oberflächenaktive Verbindungen und ihre Anwendungen | |
| JPS5984821A (ja) | 徐溶化組成物 | |
| US2131533A (en) | Cement mass | |
| DE59108246D1 (de) | UNGESÄTTIGTE 15-DEHYDRO-17alpha-CYANOMETHYL-17beta- HYDROXYSTEROIDE | |
| JP6148875B2 (ja) | 液体急結剤、それを用いたセメント組成物および吹付け工法 | |
| US2956054A (en) | Chsco | |
| US7943668B2 (en) | Process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, and composition thus obtained | |
| KR910019625A (ko) | 뼈의 무기질 소실을 억제하는 방법 | |
| JP2007246514A (ja) | ピペラシリンナトリウムの新規な結晶 | |
| Schmitz et al. | Ring opening and ring enlargement of a cyclopropene carboxylic acid |